Could longer infusions make chemo safer for frail patients?

NCT ID NCT05183126

Recruiting now Knowledge-focused Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at whether giving the chemotherapy drug paclitaxel over a longer period (2-3 hours instead of 1 hour) can help cancer patients with low muscle mass achieve safer drug levels. Researchers will compare drug concentrations in 22 women with breast, stomach, or esophageal cancer. The goal is to see if adjusting infusion time based on muscle mass normalizes exposure to the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel (Taxol)
What this could lead to: If successful, this could lead to safer and more effective dosing of paclitaxel for cancer patients with low muscle mass.
What could go wrong: This is a small, early-phase pharmacokinetic study with only 22 participants. It focuses on drug levels, not direct treatment outcomes, so benefits for patients are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric carcinoma gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER ESOPHAGEAL CANCER METASTATIC GASTRIC CANCER

Contacts and locations

Locations

University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.